Search research articles
Contact Us
Filters
Showing results (31-40 of 49) with videos related to
Page
of 5
Sort By:
Leukemia & Lymphoma
|
July 1, 1996
Idarubicin and high dose cytarabine: a new salvage treatment for refractory or relapsing non-Hodgkin's lymphoma
P Dufour, R Mors, P Berthaud, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 1, 1996
Is the small non-cleaved-cell lymphoma histologic subtype a poor prognostic factor in adult patients? A case-controlled analysis. The Groupe d'Etude des Lymphomes de l'Adulte
M Diviné, E Lepage, J Brière, et al.
Bone Marrow Transplantation
|
July 5, 2011
Autologous transplantation in CLL patients with B and C Binet stages: final results of the prospective randomized GOELAMS LLC 98 trial
A Brion, B Mahé, B Kolb, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 5, 2013
A phase III adjuvant randomised trial of 6 cycles of 5-fluorouracil-epirubicine-cyclophosphamide (FEC100) versus 4 FEC 100 followed by 4 Taxol (FEC-T) in node positive breast cancer patients (Trial B2000)
C Delbaldo, D Serin, M Mousseau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 15, 1998
Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a multicenter phase II trial. Groupe Français d'Immunothérapie
A Ravaud, B Audhuy, F Gomez, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
March 10, 2001
Prognostic factors in ovarian carcinoma in complete histologic remission at second-look surgery
D. Hamid, B. Duclos, J. C. Barats, et al.
Bulletin Du Cancer
|
July 1, 1996
[Carboplatin and cyclophosphamide in stage Ic-IV ovarian carcinoma: retrospective study of 101 cases]
T Petit, P Dufour, J C Barrats, et al.
British Journal of Haematology
|
July 23, 1998
Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients
P Moreau, V Leblond, P Bourquelot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 1, 1996
5-Fluorouracil versus 5-fluorouracil plus alpha-interferon as treatment of metastatic colorectal carcinoma. A randomized study
P Dufour, F Husseini, B Dreyfus, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 14, 2004
Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer
P Fumoleau, R Largillier, C Clippe, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 49) with videos related to
Sort By:
Page
of 5
Leukemia & Lymphoma
|
July 1, 1996
Idarubicin and high dose cytarabine: a new salvage treatment for refractory or relapsing non-Hodgkin's lymphoma
P Dufour, R Mors, P Berthaud, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 1, 1996
Is the small non-cleaved-cell lymphoma histologic subtype a poor prognostic factor in adult patients? A case-controlled analysis. The Groupe d'Etude des Lymphomes de l'Adulte
M Diviné, E Lepage, J Brière, et al.
Bone Marrow Transplantation
|
July 5, 2011
Autologous transplantation in CLL patients with B and C Binet stages: final results of the prospective randomized GOELAMS LLC 98 trial
A Brion, B Mahé, B Kolb, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 5, 2013
A phase III adjuvant randomised trial of 6 cycles of 5-fluorouracil-epirubicine-cyclophosphamide (FEC100) versus 4 FEC 100 followed by 4 Taxol (FEC-T) in node positive breast cancer patients (Trial B2000)
C Delbaldo, D Serin, M Mousseau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 15, 1998
Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a multicenter phase II trial. Groupe Français d'Immunothérapie
A Ravaud, B Audhuy, F Gomez, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
March 10, 2001
Prognostic factors in ovarian carcinoma in complete histologic remission at second-look surgery
D. Hamid, B. Duclos, J. C. Barats, et al.
Bulletin Du Cancer
|
July 1, 1996
[Carboplatin and cyclophosphamide in stage Ic-IV ovarian carcinoma: retrospective study of 101 cases]
T Petit, P Dufour, J C Barrats, et al.
British Journal of Haematology
|
July 23, 1998
Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients
P Moreau, V Leblond, P Bourquelot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 1, 1996
5-Fluorouracil versus 5-fluorouracil plus alpha-interferon as treatment of metastatic colorectal carcinoma. A randomized study
P Dufour, F Husseini, B Dreyfus, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 14, 2004
Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer
P Fumoleau, R Largillier, C Clippe, et al.
Page
of 5